Search

Displaying results 3231 - 3240 of 9886 in total
  1. Drug

    Chlormadinone

    go.drugbank.com/drugs/DB13528
    Investigational

    Mixtures: ADELLA MINI TABLETA CON RECUBRIMIENTO DE GELATINA, ADELLA MINI TABLETA CON RECUBRIMIENTO DE GELATINA
  2. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  3. Drug

    Dimethicone 410

    go.drugbank.com/drugs/DB14005
    Approved

    Dimethicone is a silicone-based polymer used as a moisturizer in different skin OTC products.[A32462] It is formed by repeated polymeric units of -(CH3)2SiO- with a terminal trimethyl siloxy unit. … [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.

  4. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel]. … [A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.

  5. Drug

    Theobromine

    go.drugbank.com/drugs/DB01412
    Investigational

    A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than theophylline and is also a less powerful stimulant of smooth muscle. … It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)

  6. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type … 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.

  7. Drug

    Ceritinib

    go.drugbank.com/drugs/DB09063
    ApprovedInvestigational

    Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. … The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    in pregnancy due to a perceived lower risk of teratogenic effects. … Methimazole is a thionamide antithyroid agent that inhibits the synthesis of thyroid hormones.

  9. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: gent-L-tip, Pedia-Lax
  10. Drug

    Bisoctrizole

    go.drugbank.com/drugs/DB11262
    Approved

    Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays.